The issue of whether an invention claimed in a patent is obvious (occasioning the patent liable to be revoked) was at the core of the High Court decision in Aktiebolaget Hässle v Alphapharm handed down on 12 December 2002. The High Court by majority overturned a unanimous Full Federal Court decision that had upheld the primary judge’s finding that the patent in question was obvious.
The appellants, members of the Astra pharmaceutical group ("Astra"), were the patentee and exclusive licensee of a patent for an oral formulation containing omeprazole, a compound found to be effective in treating stomach ulcers. The patent was granted under the Patents Act 1952, and accordingly that Act applied. The respondent, Alphapharm, distributed generic drugs and wished to import and sell in Australia a generic form of Astra’s patented omeprazole formulation. Astra commenced infringement proceedings against Alphapharm, which by its cross-claim sought revocation of Astra’s patent.